Figure 3From: A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss Probability that staying on branded risperidone will be cost-effective (at a WTP of €40,000 per QALY gained) compared to generic substitution (at various levels of probability of becoming non-compliant after generic substitution and with various number of patients included).Back to article page